The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure
Open accessAbstract
Background— The hematopoietic cytokine erythropoietin has cytoprotective effects in endothelial cells in vitro that are mediated through direct activation of the pro-survival Akt tyrosine kinase signaling pathway. We tested the hypothesis that low-dose therapy with the long-acting recombinant human erythropoietin analogue darbepoetin alpha protects vascular endothelium in vivo in a classic remnant kidney rat model characterized by severe endothelial damage, progressive vascular sclerosis, and ischemia-induced tissue fibrosis. Methods and Results— Using a parallel group study design, we randomly assigned animals after 5/6 nephrectomy to treatment with either saline (n=36) or 0.1 μg/kg body wt darbepoetin (n=24) subcutaneously once weekly. We monitored hematocrit, blood pressure, and serum creatinine regularly and obtained renal tissue 6 weeks after nephrectomy for morphological and immunohistochemical analysis. Darbepoetin-treated animals had significantly improved survival compared with saline-treated controls (63% versus 33%; P <0.05), although hematocrit levels were similar in both groups. Darbepoetin treatment ameliorated endothelial damage; attenuated the composite tissue injury score (saline 1.9±0.4; darbepoetin 0.4±0.2; P <0.001), which included vascular sclerosis, glomerulosclerosis, and tubulointerstitial damage; and preserved renal function. We found persistent activation of the pro-survival Akt signaling pathway in endothelial and epithelial glomerular cells in darbepoetin-treated animals, accompanied by a significant reduction of apoptotic cell death in renal tissue. Conclusions— Low-dose darbepoetin treatment confers vascular and tissue protection that is associated with persistent stimulation of the pro-survival Akt signaling pathway. The use of recombinant human erythropoietin or analogues may have utility in preventing ischemia-related progressive vascular injury and organ failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Cited by
Wolf, G. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2004.01429.x · Cited by 360
Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise
Brines, M., & Cerami, A. (2006) · Kidney International · doi:10.1038/sj.ki.5001546 · Cited by 290
Role of hypoxia in the pathogenesis of renal disease
Eckardt, K.-U., Bernhardt, W. W., Weidemann, A., Warnecke, C., Rosenberger, C., Wiesener, M. M., & Willam, C. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09909.x · Cited by 277
van der Meer, P., Lipsic, E., Henning, R. H., Boddeus, K., van der Velden, J., Voors, A. A., van Veldhuisen, D. J., van Gilst, W. H., & Schoemaker, R. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.044 · Cited by 257
Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress
Katavetin, P., Inagi, R., Miyata, T., Shao, J., Sassa, R., Adler, S., Eto, N., Kato, H., Fujita, T., & Nangaku, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.207 · Cited by 84
Metadata
- Authors
- Bahlmann, F. H., Song, R., Boehm, S. M., Mengel, M., von Wasielewski, R., Lindschau, C., Kirsch, T., de Groot, K., Laudeley, R., Niemczyk, E., Güler, F., Menne, J., Haller, H., & Fliser, D.
- Venue
- Circulation
- Published
- 2004-08-24
- Volume
- 110
- Issue
- 8
- Pages
- 1006-1012
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2109674240
- Cited by
- 187
- References
- 1
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure. https://app.cochat.ai/papers/10.1161/01.cir.0000139335.04152.f3
- The paper
- Bahlmann, F. H., Song, R., Boehm, S. M., Mengel, M., von Wasielewski, R., Lindschau, C., Kirsch, T., de Groot, K., Laudeley, R., Niemczyk, E., Güler, F., Menne, J., Haller, H., & Fliser, D. (2004). Low-Dose Therapy With the Long-Acting Erythropoietin Analogue Darbepoetin Alpha Persistently Activates Endothelial Akt and Attenuates Progressive Organ Failure. Circulation. https://doi.org/10.1161/01.cir.0000139335.04152.f3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.